The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|January 11, 2016
Shire Acquires Baxalta in $32 Billion Deal
Author(s)Pharmaceutical Technology Editors
Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.
Advertisement
Shire and Baxalta have announced $32 billion agreement under which Shire will combine with Baxalta, creating a company with the top rare diseases platform in revenue and pipeline depth, the companies reported in a Jan. 11, 2016 press statement. The new company is projected to achieve annual revenues of $20 billion by 2020.
Shire reports that the combined companies will have products in growing franchises in hematology; immunology; neuroscience; lysosomal storage diseases; gastrointestinal/endocrine; hereditary angioedema; and oncology; as well as a late-stage ophthalmics pipeline.
Baxalta shareholders will hold approximately 34% ownership in the combined company. The parties expect the transaction to close mid-2016.
Source:
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement